The following information has been recovered from the Consensus Statement that is currently supported by 91 scientists, clinicians, and public health professionals worldwide, and reflects their concerns.
The relationships between prenatal acetaminophen (APAP) exposure and adverse neurodevelopmental outcomes have been investigated in 29 observational studies including over 220,000 mother–child pairs worldwide.
Twenty-six of these studies 26 identified positive associations between APAP exposure during pregnancy and parent-reported neurodevelopmental outcomes, primarily ADHD and related behavioral abnormalities, but also ASD, language delays, decreased IQ, cerebral palsy, oppositional–defiant disorder, decreased executive function, and conduct disorders.1
A 2021 study using data from the Boston Birth Cohort evaluated the association between levels of APAP metabolites in umbilical cord plasma (direct evidence of fetal exposure) and physician-diagnosed childhood ADHD, ASD, and other developmental disabilities.5
A 2020 prospective cohort study conducted in Québec, Canada, concluded that prenatal APAP exposure was also associated with increased negative connectivity between the left prefrontal cortex (frontoparietal seed) and the right precentral gyrus, which mediated the association of APAP with hyperactivity. This study established for the first time an association between prenatal APAP exposure and a physical manifestation of neurological alteration.6
In October 2019, a study published in the medical journal JAMA Psychiatry found that children with the highest levels of acetaminophen metabolites in their blood at birth had the highest risk of developmental disorders.7
In another cohort study of 996 mother-infant dyads from the Boston Birth Cohort, cord plasma biomarkers of fetal exposure to acetaminophen were associated with significantly increased risk of childhood ADHD and ASD.8
According to additional research published in the European Journal of Epidemiology in June 2021, children exposed to Tylenol during pregnancy were 19% more likely to have ASDs and 21% more likely to have ADHD symptoms, when compared to non-exposed children.7
1. Bauer, AZ., et al. Paracetamol use during pregnancy–a Call for precautionary action. Nat. Rev. Endocrinol. 17, 757–766 (2021)
2. Bauer, AZ. et al. Prenatal paracetamol exposure and child neurodevelopment: a review. Horm. Behav. 101, 125–147 (2018).
3. Markets and Research. Global Acetaminophen Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026. Marketsandresearch.biz https://www.marketsandresearch.biz/report/43101/global-acetaminophen-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2026 (2020)
4. Zablotsky, B. et al. Prevalence and trends of developmental disabilities among children in the US: 2009–2017. Pediatrics 144, e20190811 (2019).
5. Yuelong, JI. et al. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in childhood. JAMA Psychiatry. 77, 180–189 (2020).
6. Baker, BH. et al. Association of prenatal acetaminophen exposure measured in meconium with risk of attention-deficit/hyperactivity disorder mediated by frontoparietal network brain connectivity. JAMA Pediatr. 174, 1073–1081 (2020).
7. About Lawsuits. Extension Granted For Responses to MDL Motion for Acetaminophen Autism, ADHD Lawsuits. Retrieved from https://www.aboutlawsuits.com/acetaminophen-autism-mdl-extension/ (2022).
8. Yuelong JI, (2020). “Cord Plasma Biomarkers of in Utero Acetaminophen Exposure and ADHD and ASD Risk.” JAMA Psychiatry, JAMA Network. Retrieved from https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2753512
9. Miller & Zois, LLC https://www.lawsuit-information-center.com/tylenol-autism-lawsuit.html (2022)
10. Claudia, BAG. et al. Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms. Int. J. Epidemiol. 45, 6, 1987–1996 (2016)